Insulin-like peptides signaling in Alzheimer's disease: On the road to alternative therapeutics

Current Opinion in Behavioral Sciences

Volumn 9, Issue , 2016, Pages 15-25

  Trueba Saiz, Angel ^a   Aleman, Ignacio Torres ^a  

^a INSTITUTO CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE RELEASING FACTOR DERIVATIVE; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLULISINE; PLACEBO; SOMATOMEDIN B; SOMATOMEDIN C;

ALZHEIMER DISEASE; ARTICLE; COGNITION; DIABETES MELLITUS; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC);

EID: 84949266557     PISSN: None     EISSN: 23521546     Source Type: Journal    
DOI: 10.1016/j.cobeha.2015.11.013     Document Type: Review

References (89)

1. Fernandez AM, Torres-Aleman I: The many faces of insulin-like peptide signalling in the brain. Nat Rev Neurosci 2012, 13:225-239.
2. Hasselbalch SG, Knudsen GM, Videbaek C, Pinborg LH, Schmidt JF, Holm S, Paulson OB: No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes 1999, 48:1915-1921.
3. Kleinridders A, Ferris HA, Cai W, Kahn CR: Insulin action in brain regulates systemic metabolism and brain function. Diabetes 2014, 63:2232-2243.
4. Gasparini L, Xu H: Potential roles of insulin and IGF-1 in Alzheimer's disease. Trends Neurosci 2003, 26:404-406.
5. Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, Silverman MA, Kazi H, Melo HM, McClean PL et al.: An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Abeta oligomers. J Clin Invest 2012, 122:1339-1353.
6. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS et al.: Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012, 122:1316-1338.
7. Blum-Degen D, Frolich L, Hoyer S, Riederer P: Altered regulation of brain glucose metabolism as a cause of neurodegenerative disorders? J Neural Transm Suppl 1995, 46:139-147.
8. Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, Callaghan M, Arbuckle M, Behl C, Craft S: Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. J Alzheimers Dis 2015, 44:897-906.
9. Wadman M: US government sets out Alzheimer's plan. Nature 2012, 485:426-427.
10. Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV: Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol 2012, 69:1420-1429.
11. Bassil F, Fernagut PO, Bezard E, Meissner WG: Insulin IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification? Prog Neurobiol 2014, 118:1-18.
12. Musiek ES, Holtzman DM: Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. Nat Neurosci 2015: 800-806.
13. Kuwabara T, Kagalwala MN, Onuma Y, Ito Y, Warashina M, Terashima K, Sanosaka T, Nakashima K, Gage FH, Asashima M: Insulin biosynthesis in neuronal progenitors derived from adult hippocampus and the olfactory bulb. EMBO Mol Med 2011, 3:742-754.
14. Nishijima T, Piriz J, Duflot S, Fernandez AM, Gaitan G, Gomez- Pinedo U, Verdugo JM, Leroy F, Soya H, Nunez A, Torres-Aleman I: Neuronal activity drives localized blood-brain-barrier transport of serum insulin-like growth factor-I into the CNS. Neuron 2010, 67:834-846.
15. Gray SM, Meijer RI, Barrett EJ: Insulin regulates brain function, but how does it get there? Diabetes 2014, 63:3992-3997.
16. Ziegler AN, Levison SW, Wood TL: Insulin and IGF receptor signalling in neural-stem-cell homeostasis. Nat Rev Endocrinol 2015, 11:161-170.
17. Cholerton B, Baker LD, Craft S: Insulin, cognition, and dementia. Eur J Pharmacol 2013, 719:170-179.
18. Freiherr J, Hallschmid M, Frey WH, Brunner YF, Chapman CD, Holscher C, Craft S, De Felice FG, Benedict C: Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs 2013, 27:505-514.
19. Chen DY, Stern SA, Garcia-Osta A, Saunier-Rebori B, Pollonini G, Bambah-Mukku D, Blitzer RD, Alberini CM: A critical role for IGFII in memory consolidation and enhancement. Nature 2011, 469:491-497.
20. Stern SA, Kohtz AS, Pollonini G, Alberini CM: Enhancement of memories by systemic administration of insulin-like growth factor II. Neuropsychopharmacology 2014, 39:2179-2190.
21. Martin ED, Sanchez-Perez A, Trejo JL, Martin-Aldana JA, Cano JM, Pons S, Acosta UC, Menes L, White MF, Burks DJ: IRS- 2 deficiency impairs NMDA receptor-dependent long-term potentiation. Cereb Cortex 2012, 22:1717-1727.
22. Molina DP, Ariwodola OJ, Weiner JL, Brunso-Bechtold JK, Adams MM: Growth hormone and insulin-like growth factor-I alter hippocampal excitatory synaptic transmission in young and old rats. Age (Dordr) 2013, 35:1575-1587.
23. Banks WA, Owen JB, Erickson MA: Insulin in the brain: there and back again. Pharmacol Ther 2012, 136:82-93.
24. Schmeisser MJ, Baumann B, Johannsen S, Vindedal GF, Jensen V, Hvalby OC, Sprengel R, Seither J, Maqbool A, Magnutzki A et al.: IkappaB kinase/nuclear factor kappaBdependent insulin-like growth factor 2 (Igf2) expression regulates synapse formation and spine maturation via Igf2 receptor signaling. J Neurosci 2012, 32:5688-5703.
25. Kim B, Figueroa-Romero C, Pacut C, Backus C, Feldman EL: Insulin resistance prevents AMPK-induced tau dephosphorylation through Akt-mediated increase in AMPKSer485 phosphorylation. J Biol Chem 2015, 290:19146-19157.
26. Clarke JR, Lyra E, Silva NM, Figueiredo CP, Frozza RL, Ledo JH, Beckman D, Katashima CK, Razolli D, Carvalho BM et al.: Alzheimer-associated Abeta oligomers impact the central nervous system to induce peripheral metabolic deregulation. EMBO Mol Med 2015, 7:190-210.
27. Arrieta-Cruz I, Knight CM, Gutierrez-Juerez R: Acute exposure of the mediobasal hypothalamus to amyloid-beta25-35 perturbs hepatic glucose metabolism. J Alzheimers Dis 2015, 46:843-848.
28. De Felice FG, Ferreira ST: Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 2014, 63:2262-2272.
29. Proitsi P, Lupton MK, Velayudhan L, Hunter G, Newhouse S, Lin K, Fogh I, Tsolaki M, Daniilidou M, Pritchard M et al.: Alleles that increase risk for type 2 diabetes mellitus are not associated with increased risk for Alzheimer's disease. Neurobiol Aging 2014, 35:2883.
30. Strachan MW, Reynolds RM, Marioni RE, Price JF: Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nat Rev Endocrinol 2011, 7:108-114.
31. Suzuki R, Ferris HA, Chee MJ, Maratos-Flier E, Kahn CR: Reduction of the cholesterol sensor SCAP in the brains of mice causes impaired synaptic transmission and altered cognitive function. PLoS Biol 2013, 11:e1001532.
32. Liu Z, Patil IY, Jiang T, Sancheti H, Walsh JP, Stiles BL, Yin F, Cadenas E: High-fat diet induces hepatic insulin resistance and impairment of synaptic plasticity. PLoS ONE 2015, 10:e0128274.
33. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van EJ, Wolfing H, Chieng BC, Christie MJ, Napier IA et al.: Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010, 142:387-397.
34. Bhat NR, Thirumangalakudi L: Increased tau phosphorylation and impaired brain insulin/IGF signaling in mice fed a high fat/ high cholesterol diet. J Alzheimers Dis 2013, 36:781-789.
35. Leboucher A, Laurent C, Fernandez-Gomez FJ, Burnouf S, Troquier L, Eddarkaoui S, Demeyer D, Caillierez R, Zommer N, Vallez E et al.: Detrimental effects of diet-induced obesity on tau pathology are independent of insulin resistance in tau transgenic mice. Diabetes 2013, 62:1681-1688.
36. Lee CW, Shih YH, Wu SY, Yang T, Lin C, Kuo YM: Hypoglycemia induces tau hyperphosphorylation. Curr Alzheimer Res 2013, 10:298-308.
37. Becker K, Freude S, Zemva J, Stohr O, Krone W, Schubert M: Chronic peripheral hyperinsulinemia has no substantial influence on tau phosphorylation in vivo. Neurosci Lett 2012, 516:306-310.
38. Gil-Bea FJ, Solas M, Solomon A, Mugueta C, Winblad B, Kivipelto M, Ramirez MJ, Cedazo-Minguez A: Insulin levels are decreased in the cerebrospinal fluid of women with prodomal Alzheimer's disease. J Alzheimers Dis 2010, 22:405-413.
39. Johansson P, Aberg D, Johansson JO, Mattsson N, Hansson O, Ahren B, Isgaard J, Aberg ND, Blennow K, Zetterberg H et al.: Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease. Psychoneuroendocrinology 2013, 38:1729-1737.
40. Trueba-Saiz A, Cavada C, Fernandez AM, Leon T, Gonzalez DA, Fortea OJ, Lleo A, Del ST, Nunez A, Torres-Aleman I: Loss of serum IGF-I input to the brain as an early biomarker of disease onset in Alzheimer mice. Transl Psychiatry 2013, 3:e330.
41. Hertze J, Nagga K, Minthon L, Hansson O: Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer's disease: an observational study. BMC Neurol 2014, 14:64.
42. Ninomiya T: Diabetes mellitus and dementia. Curr Diab Rep 2014, 14:487.
43. Weinstein G, Maillard P, Himali JJ, Beiser AS, Au R, Wolf PA, Seshadri S, DeCarli C: Glucose indices are associated with cognitive and structural brain measures in young adults. Neurology 2015, 84:2329-2337.
44. Dumurgier J, Paquet C, Peoc'h K, Lapalus P, Mouton-Liger F, Benisty S, Chasseigneaux S, Chabriat H, Hugon J: CSF Abeta(1)(S)(4)(2) levels and glucose metabolism in Alzheimer's disease. J Alzheimers Dis 2011, 27:845-851.
45. Patrone C, Eriksson O, Lindholm D: Diabetes drugs and neurological disorders: new views and therapeutic possibilities. Lancet Diabetes Endocrinol 2014, 2:256-262.
46. Carro E, Torres-Aleman I: The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur J Pharmacol 2004, 490:127-133.
47. Moloney AM, Griffin RJ, Timmons S, O'Connor R, Ravid R, O'Neill C: Defects in IGF-1 receptor, insulin receptor and IRS-1/ 2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 2010, 31:224-243.
48. Yarchoan M, Toledo JB, Lee EB, Arvanitakis Z, Kazi H, Han LY, Louneva N, Lee VM, Kim SF, Trojanowski JQ, Arnold SE: Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies. Acta Neuropathol 2014, 128:679-689.
49. Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S: Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol 2010, 68:51-57.
50. Kleinridders A, Cai W, Cappellucci L, Ghazarian A, Collins WR, Vienberg SG, Pothos EN, Kahn CR: Insulin resistance in brain alters dopamine turnover and causes behavioral disorders. Proc Natl Acad Sci USA 2015, 112:3463-3468.
51. Wu X, Li R, Fleisher AS, Reiman EM, Guan X, Zhang Y, Chen K, Yao L: Altered default mode network connectivity in Alzheimer's disease - a resting functional MRI and Bayesian network study. Hum Brain Mapp 2011, 32:1868-1881.
52. Kenna H, Hoeft F, Kelley R, Wroolie T, DeMuth B, Reiss A, Rasgon N: Fasting plasma insulin and the default mode network in women at risk for Alzheimer's disease. Neurobiol Aging 2013, 34:641-649.
53. Clemmons DR: Role of insulin-like growth factor iin maintaining normal glucose homeostasis. Horm Res 2004, 62(Suppl1):77-82.
54. Doi T, Shimada H, Makizako H, Tsutsumimoto K, Hotta R, Nakakubo S, Suzuki T: Association of insulin-like growth factor-1 with mild cognitive impairment and slow gait speed. Neurobiol Aging 2014, 36:942-947.
55. Aleman A, Torres-Aleman I: Circulating insulin-like growth factor I and cognitive function: neuromodulation throughout the lifespan. Prog Neurobiol 2009, 89:256-265.
56. Torres-Aleman I: Mouse models of Alzheimer's dementia: current concepts and new trends. Endocrinology 2008, 149:5952-5957.
57. Devi L, Alldred MJ, Ginsberg SD, Ohno M: Mechanisms underlying insulin deficiency-induced acceleration of betaamyloidosis in a mouse model of Alzheimer's disease. PLoS ONE 2012, 7:e32792.
58. Poirier R, Fernandez AM, Torres-Aleman I, Metzger F: Early brain amyloidosis in APP/PS1 mice with serum insulin-like growth factor-I deficiency. Neurosci Lett 2012, 509:101-104.
59. Ramos-Rodriguez JJ, Ortiz-Barajas O, Gamero-Carrasco C, de la Rosa PR, Infante-Garcia C, Zopeque-Garcia N, Lechuga-Sancho AM, Garcia-Alloza M: Prediabetes-induced vascular alterations exacerbate central pathology in APPswe/PS1dE9 mice. Psychoneuroendocrinology 2014, 48:123-135.
60. Vandal M, White PJ, Tremblay C, St-Amour I, Chevrier G, Emond V, Lefrancois D, Virgili J, Planel E, Giguere Y et al.: Insulin reverses the high-fat diet-induced increase in brain Abeta and improves memory in an animal model of Alzheimer disease. Diabetes 2014, 63:4291-4301.
61. O'Connor T, Sadleir KR, Maus E, Velliquette RA, Zhao J, Cole SL, Eimer WA, Hitt B, Bembinster LA, Lammich S et al.: Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis. Neuron 2008, 60:988-1009.
62. van der Harg JM, Nolle A, Zwart R, Boerema AS, van Haastert ES, Strijkstra AM, Hoozemans JJ, Scheper W: The unfolded protein response mediates reversible tau phosphorylation induced by metabolic stress. Cell Death Dis 2014, 5:e1393.
63. Liu CC, Hu J, Tsai CW, Yue M, Melrose HL, Kanekiyo T, Bu G: Neuronal LRP1 regulates glucose metabolism and insulin signaling in the brain. J Neurosci 2015, 35:5851-5859.
64. Kanekiyo T, Cirrito JR, Liu CC, Shinohara M, Li J, Schuler DR, Shinohara M, Holtzman DM, Bu G: Neuronal clearance of amyloid-beta by endocytic receptor LRP1. J Neurosci 2013, 33:19276-19283.
65. Manolopoulos KN, Klotz LO, Korsten P, Bornstein SR, Barthel A: Linking Alzheimer's disease to insulin resistance: the FoxO response to oxidative stress. Mol Psychiatry 2010, 15:1046-1052.
66. Lee Y, Kim YH, Park SJ, Huh JW, Kim SH, Kim SU, Kim JS, Jeong KJ, Lee KM, Hong Y et al.: Insulin/IGF signaling-related gene expression in the brain of a sporadic Alzheimer's disease monkey model induced by intracerebroventricular injection of streptozotocin. J Alzheimers Dis 2014, 38:251-267.
67. Pearson-Leary J, McNay EC: Intrahippocampal administration of amyloid-beta(1-42) oligomers acutely impairs spatial working memory, insulin signaling, and hippocampal metabolism. J Alzheimers Dis 2012, 30:413-422.
68. Chen Z, Zhong C: Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: Implications for diagnostic and therapeutic strategies. Prog Neurobiol 2013, 108C:21-43.
69. Winkler EA, Nishida Y, Sagare AP, Rege SV, Bell RD, Perlmutter D, Sengillo JD, Hillman S, Kong P, Nelson AR et al.: GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration. Nat Neurosci 2015, 18:521-530 advance online publication.
70. Monacelli F, Borghi R, Cammarata S, Nencioni A, Piccini A, Tabaton M, Odetti P: Amnestic mild cognitive impairment and conversion to Alzheimer's disease: insulin resistance and glycoxidation as early biomarker clusters. J Alzheimers Dis 2015, 45:89-95.
71. Birks JS, Chong LY, Grimley EJ: Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2015, 9:CD001191.
72. Benarroch EE: Insulin-like growth factors in the brain and their potential clinical implications. Neurology 2012, 79:2148-2153.
73. Picone P, Giacomazza D, Vetri V, Carrotta R, Militello V, Biagio PL, Di CM: Insulin-activated Akt rescues Abeta oxidative stressinduced cell death by orchestrating molecular trafficking. Aging Cell 2011, 10:832-843.
74. Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, Antikainen R, Backman L, Hanninen T, Jula A, Laatikainen T et al.: A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 2015, 385:2255-2263.
75. Maimaiti S, Anderson KL, DeMoll C, Brewer LD, Rauh BA, Gant JC, Blalock EM, Porter NM, Thibault O: Intranasal insulin improves age-related cognitive deficits and reverses electrophysiological correlates of brain aging. J Gerontol Series A: Biol Sci Med Sci 2015 http://dx.doi.org/10.1093/gerona/ glu314.
76. Adzovic L, Lynn AE, D'Angelo HM, Crockett AM, Kaercher RM, Royer SE, Hopp SC, Wenk GL: Insulin improves memory and reduces chronic neuroinflammation in the hippocampus of young but not aged brains. J Neuroinflamm 2015, 12:63.
77. Chen Y, Zhao Y, Dai CL, Liang Z, Run X, Iqbal K, Liu F, Gong CX: Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces Abeta level and microglia activation in the brains of 3xTg-AD mice. Exp Neurol 2014, 261:610-619.
78. Zhang H, Hao Y, Manor B, Novak P, Milberg W, Zhang J, Fang J, Novak V: Intranasal insulin enhanced resting-state functional connectivity of hippocampal regions in type 2 diabetes. Diabetes 2015, 64:1025-1034.
79. Brunner YF, Kofoet A, Benedict C, Freiherr J: Central insulin administration improves odor-cued reactivation of spatial memory in young men. J Clin Endocrinol Metab 2015, 100:212-219.
80. Schilling TM, Ferreira de Sa DS, Westerhausen R, Strelzyk F, Larra MF, Hallschmid M, Savaskan E, Oitzl MS, Busch HP, Naumann E, Schachinger H: Intranasal insulin increases regional cerebral blood flow in the insular cortex in men independently of cortisol manipulation. Hum Brain Mapp 2014, 35:1944-1956.
81. Carro E, Trejo JL, Gerber A, Loetscher H, Torrado J, Metzger F, Torres-Aleman I: Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis. Neurobiol Aging 2006, 27:1250-1257.
82. Lanz TA, Salatto CT, Semproni AR, Marconi M, Brown TM, Richter KE, Schmidt K, Nelson FR, Schachter JB: Peripheral elevation of IGF-1 fails to alter Abeta clearance in multiple in vivo models. Biochem Pharmacol 2008, 75:1093-1103.
83. El-Ami T, Moll L, Carvalhal Marques F, Volovik Y, Reuveni H, Cohen E: A novel inhibitor of the insulin/IGF signaling pathway protects from age-onset, neurodegeneration-linked proteotoxicity. Aging Cell 2014, 13:165-174.
84. Gontier G, George C, Chaker Z, Holzenberger M, Aid S: Blocking IGF signaling in adult neurons alleviates Alzheimer's disease pathology through amyloid-beta clearance. J Neurosci 2015, 35:11500-11513.
85. Lopez-Lopez C, Dietrich MO, Metzger F, Loetscher H, Torres- Aleman I: Disturbed cross talk between insulin-like growth factor I and AMP-activated protein kinase as a possible cause of vascular dysfunction in the amyloid precursor protein/ presenilin 2 mouse model of Alzheimer's disease. J Neurosci 2007, 27:824-831.
86. Puche JE, Castilla-Cortazar I: Human conditions of insulin-like growth factor-I (IGF-I) deficiency. J Transl Med 2012, 10:224.
87. Miller G: Stopping Alzheimer's before it starts. Science 2012, 337:790-792.
88. Sevigny JJ, Ryan JM, Van Dyck CH, Peng Y, Lines CR, Nessly ML: Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology 2008, 71:1702-1708.
89. Yarchoan M, Arnold SE: Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes 2014, 63:2253-2261.